Simulations Plus, Inc. (SLP) Reached 1-Year High on Jun, 26 at $23.60

June 26, 2018 - By Gregory Tomko

Simulations Plus, Inc. (NASDAQ:SLP) Corporate Logo

Big Money Sentiment decreased to 1.5 in Q1 2018. It has change of 0.06, from 2017Q4’s 1.56. The ratio dropped due to Simulations Plus, Inc. positioning: 5 sold and 21 reduced. 12 funds took holdings and 27 increased holdings. Investors holded 5.50 million in 2017Q4 but now own 5.63 million shares or 2.37% more.
Dimensional Fund Advisors L P invested in 0% or 475,216 shs. Amer Intl Grp holds 0% or 6,991 shs. Alabama-based Stanley has invested 0.21% in Simulations Plus, Inc. (NASDAQ:SLP). Cadence Capital Mngmt Ltd Liability Corp reported 0.12% of its capital in Simulations Plus, Inc. (NASDAQ:SLP). Panagora Asset holds 0% of its capital in Simulations Plus, Inc. (NASDAQ:SLP) for 67,763 shs. Pnc Fincl Svcs holds 23,028 shs or 0% of its capital. The Illinois-based Northern Tru has invested 0% in Simulations Plus, Inc. (NASDAQ:SLP). Millennium Ltd Liability Corporation holds 0% in Simulations Plus, Inc. (NASDAQ:SLP) or 51,011 shs. Whalerock Point Partners Ltd accumulated 0.17% or 35,905 shs. Great West Life Assurance Can has invested 0% in Simulations Plus, Inc. (NASDAQ:SLP). 32,239 are owned by Tiaa Cref Inv Management Limited Com. Wedge Cap L Lp Nc reported 45,500 shs stake. Morgan Stanley invested 0% in Simulations Plus, Inc. (NASDAQ:SLP). Bancorp Of New York Mellon holds 0% or 77,077 shs in its capital. California-based Granite Investment Prns Ltd Limited Liability Company has invested 0.04% in Simulations Plus, Inc. (NASDAQ:SLP).

Simulations Plus, Inc. had 5 selling transactions and 0 insider buys since February 26, 2018. This’s net activity of $1.29 million. KNEISEL JOHN ROBERT had sold 2,991 shs worth $52,766 on Friday, April 20.

Simulations Plus, Inc. (NASDAQ:SLP) touched $23.60 price per share also a 1-year high. reported it on Jun, 26. The company has $408.89M MC. The valuation of NASDAQ:SLP can change by $28.62M if our $25.25 PT is touched.

The stock increased 0.43% or $0.1 during the last trading session, reaching $23.6.Simulations Plus, Inc. has volume of 40,219 shares. Since June 26, 2017 SLP has risen 69.10% and is uptrending. SLP outperformed the S&P 500 by 56.53%.

Simulations Plus, Inc. (NASDAQ:SLP)’s earnings report is awaited by WallStreet on July, 9, according to Faxor. This year’s EPS analyst estimate is awaited to be $0.12. That is 7.69 % down compareed to $0.13 EPS for last year. This could hit $2.08M profit for SLP assuming the current $0.12 EPS will become reality. Wall Street now sees 9.09 % EPS growth despite Simulations Plus, Inc. last quarter’s EPS of $0.11.

Another two news for Simulations Plus, Inc. (NASDAQ:SLP) were recently announced by: on June 26, 2018 with title “Simulations Plus Names Shawn O’Connor as CEO”. The other‘s article was titled “Simulations Plus (SLP) Names Shawn O’Connor as CEO” and announced on June 26, 2018.

Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation worldwide.The firm is worth $408.89 million. The firm offers GastroPlus, which simulates the absorption, pharmacokinetics , and pharmacodynamics of drugs administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments, which measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.50.11 is the P/E ratio. It also provides PKPlus, a standalone program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for NCA and compartmental PK modelling; ADMET Predictor, a chemistry computer program, which takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher that integrates with MedChem Studio and ADMET Predictor.

Simulations Plus, Inc. (NASDAQ:SLP) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.